Connor Clark & Lunn Investment Management Ltd. reduced its stake in shares of PMV Pharmaceuticals, Inc. (NASDAQ:PMVP – Free Report) by 15.9% in the fourth quarter, according to the company in its most ...

HC Wainwright reissued their buy rating on shares of PMV Pharmaceuticals (NASDAQ:PMVP – Free Report) in a report released on Thursday morning,Benzinga reports. The firm currently has a $5.00 target ...

This marks Jacobio's successful transformation from the early R&D stage to an innovation-driven value realization stage," said Dr.Yinxiang Wang, the Chairman and CEO of Jacobio Pharma. "Looking ahead ...

Although it mediates p53-driven repression through the canonical p53-p21-Rb axis, the potential for p53 to directly regulate DREAM targets independently of its transcriptional activity has not been ...

Mindrank Therapeutics (Suzhou) New Drug Research & Development Co. Ltd. has disclosed cellular tumor antigen p53 (TP53) (Y220C mutant) stabilizers reported to be useful for the treatment of cancer.

The paper titled,“Discovery of Rezatapopt (PC14586), a First-in-Class, Small-Molecule Reactivator of p53 Y220C Mutant in Development” can be accessed here . Announced a partnership with ...

Enrollment on track in Phase 2 pivotal portion of PYNNACLE clinical trial evaluating rezatapopt as monotherapy in patients with TP53 Y220C and KRAS ... therapies targeting p53, today reported ...

Enrollment on track in Phase 2 pivotal portion of PYNNACLE clinical trial evaluating rezatapopt as monotherapy in patients with TP53 Y220C and KRAS wild-type advanced ... tumor-agnostic therapies ...

Oscillatory p53 expression occurs in individual cells responding to DNA breaks. While the majority of cells exhibit the same qualitative response, quantitative features of the oscillations (e.g., ...